Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 2/20 | 0.37 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.37 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6480296 | 0.86 | PSMB8 (0.47) | KDM4EALDH1A1RAB9ASMN1; SMN2HDAC6 | |
| SCHEMBL6480262 | 0.76 | TP53 (0.46) | KDM4EALDH1A1RAB9ASMN1; SMN2CA9 | |
| SCHEMBL23775896 | 0.76 | CA9 (0.44) | KDM4EALDH1A1RAB9AHDAC6CA9 | |
| SCHEMBL23775787 | 0.75 | CYP2A6 (0.39) | KDM4ETSHRALDH1A1RAB9ACA9 | |
| SCHEMBL851242 | 0.73 | HDAC6 (0.50) | KDM4EALDH1A1RAB9ASMN1; SMN2HDAC6 | |
| SCHEMBL5229918 | 0.73 | KDM4E (0.44) | KDM4ETSHRALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL28044374 | 0.71 | PIM1 (0.56) | KDM4ETSHRRAB9ASMN1; SMN2HDAC6 | |
| SCHEMBL3252832 | 0.71 | HDAC6 (0.48) | TSHRHDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL8142145 | 0.70 | HRH3 (0.44) | KDM4ETSHRALDH1A1CA9HRH3 | |
| SCHEMBL6478966 | 0.70 | SMN1; SMN2 (0.51) | KDM4ETSHRALDH1A1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6894042-B2 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY (US) | 2005-05-17 | — | — | US | disclosed |
| EP-1476448-A2 | AZABICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20040224976-A1 | Azabicyclic compounds for the treatment of disease | WALKER DANIEL PATRICK (US) | 2004-11-11 | — | — | US | disclosed |
| US-20030232853-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-18 | — | — | US | disclosed |
| WO-2003070731-A2 | AZABICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232853-A1 | Azabicyclic compounds for the treatment of disease | TPMT, MALT1, AZI2 | KDM4E 1240/4885TSHR 2614/4885ALDH1A1 109/4885 |
| US-20040224976-A1 | Azabicyclic compounds for the treatment of disease | TPMT, MALT1, AZI2 | KDM4E 1240/4885TSHR 2614/4885ALDH1A1 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.